In a study of patients with type 2 diabetes at high cardiovascular (CV) risk, metformin use decrease the risk of all-cause mortality but had no significant effect on a composite end point of CV death, MI, or ischemic stroke.
Protective effect is driven largely by a sustained 40% decrease in estimate glomerular filtration rate to below 60 mL/min/1.73 m2.
If approved, canagliflozin would be the first drug in almost 20 years indicated to treat CKD in patients with type 2 diabetes when added to current standard of care, according to the drug’s maker.
The percentage decline in estimated glomerular filtration rate over an 8-year period was greater among those with vs without diabetes across all quintiles of protein intake.
Delayed-release Niacin may be beneficial to patients with prediabetes and type 2 diabetes.
In patients with T2DM, taking liraglutide before surgery may be associated with reduced post-op plasma glucose levels.
The FDA just approved a new short-acting insulin drug, Admelog, for patients with either T1D or T2D.
Remission was linked to 46% patients in intensive weight management programs.
Semaglutide helps patients with diabetes reduce blood glucose levels and lower body weight.
Lifestyle and clinical factors could have been misinterpreted, linking antibiotics to risk of diabetes.
